KDMN - Kadmon's Rezurock added to NCCN guidelines for Graft-Versus-Host Disease

Kadmon Holdings (NASDAQ:KDMN) announces that the National Comprehensive Cancer Network (NCCN) has added Rezurock tablets to its guidelines for Hematopoietic Cell Transplantation (HCT) in the Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease (GVHD). NCCN is a not-for-profit alliance of 31 leading cancer centers devoted to patient care, research, and education. The U.S. FDA had approved Rezurock for the treatment of chronic graft-versus-host disease ((cGVHD)), in July.

For further details see:

Kadmon's Rezurock added to NCCN guidelines for Graft-Versus-Host Disease